BEAMSTART Logo

HomeNews

Global Generics Pharma Leader Selects Kneat

GlobeNewswire LogoGlobeNewswire1w ago

Global Generics Pharma Leader Selects Kneat - GlobeNewswire

Quick Summary:

Such forward-looking information includes, but is not limited to, the relationship between Kneat and the customer, Kneat’s business development activities, the use and implementation timelines of Kneat’s software within the customer’s validation processes, the ability and intent of the customer to scale the use of Kneat’s software within the customer’s organization, and the compliance of Kneat’s platform under regulatory audit and inspection.

It also showcases the versatility of the Kneat platform, which can be leveraged to deliver additional adjacent functions".- Eddie Ryan, Chief Executive Officer of Kneat Strong customer retention has emerged as a defining characteristic for Kneat as it has grown over the past ten years to become the validation software of choice for the life sciences industry, serving the majority of the top 20 largest life sciences companies in the world.

LIMERICK, Ireland, April 09, 2025 (GLOBE NEWSWIRE) -- kneat.com, inc.(TSX: KSI) (OTCQX: KSIOF), a leader in digitizing and automating validation and quality processes, is pleased to announce that a multinational producer of generic pharmaceuticals ("the Company”) has signed a Services Agreement with Kneat to digitalize its drawing management process.

or

Article Details

Category: Technology

Markets:

Topics:

Source Website Secure: Yes (HTTPS)

News Sentiment: Negative

Fact Checked: Legitimate

Article Type: News Report

Published On: 2025-04-09 @ 21:03:00 (1 weeks ago)

News Timezone: GMT +8:00

News Source URL: globenewswire.com

Language: English

Article Length: 593 words

Reading Time: 4 minutes read

Sentences: 22 lines

Sentence Length: 27 words per sentence (average)

Platforms: Desktop Web, Mobile Web, iOS App, Android App

Copyright Owner: © GlobeNewswire

News ID: 27762793

View Article Analysis

About GlobeNewswire

Main Topics: Technology

Official Website: globenewswire.com

Update Frequency: 35 posts per day

Year Established: 1998

Headquarters: China

News Last Updated: 15 hours ago

Coverage Areas: China

Ownership: Independent Company

Publication Timezone: GMT +8:00

Content Availability: Worldwide

News Language: English

RSS Feed: Available (XML)

API Access: Available (JSON, REST)

Website Security: Secure (HTTPS)

Publisher ID: #116

Publisher Details

Frequently Asked Questions

How long will it take to read this news story?

The story "Global Generics Pharma Leader Selects Kneat" has 593 words across 22 sentences, which will take approximately 3 - 5 minutes for the average person to read.

Which news outlet covered this story?

The story "Global Generics Pharma Leader Selects Kneat" was covered 1 weeks ago by GlobeNewswire, a news publisher based in China.

How trustworthy is 'GlobeNewswire' news outlet?

GlobeNewswire is a fully independent (privately-owned) news outlet established in 1998 that covers mostly technology news.

The outlet is headquartered in China and publishes an average of 35 news stories per day.

It's most recent story was published 15 hours ago.

What do people currently think of this news story?

The sentiment for this story is currently Negative, indicating that people regard this as "bad news".

How do I report this news for inaccuracy?

You can report an inaccurate news publication to us via our contact page. Please also include the news #ID number and the URL to this story.
  • News ID: #27762793
  • URL: https://beamstart.com/news/global-generics-pharma-leader-selects-174423270070

BEAMSTART

BEAMSTART is a global entrepreneurship community, serving as a catalyst for innovation and collaboration. With a mission to empower entrepreneurs, we offer exclusive deals with savings totaling over $1,000,000, curated news, events, and a vast investor database. Through our portal, we aim to foster a supportive ecosystem where like-minded individuals can connect and create opportunities for growth and success.

© Copyright 2025 BEAMSTART. All Rights Reserved.